Novartis AG Net Total Equity Issued/Repurchased 2010-2025 | NVS
Novartis AG annual/quarterly net total equity issued/repurchased history and growth rate from 2010 to 2025. Net total equity issued/repurchased can be defined as the sum of all preferred and common equity transactions regarding a company's own stock.
- Novartis AG net total equity issued/repurchased for the quarter ending March 31, 2025 was $-2.715B, a 147.04% increase year-over-year.
- Novartis AG net total equity issued/repurchased for the twelve months ending March 31, 2025 was $-19.245B, a 15.07% decline year-over-year.
- Novartis AG annual net total equity issued/repurchased for 2024 was $-8.301B, a 3.09% decline from 2023.
- Novartis AG annual net total equity issued/repurchased for 2023 was $-8.566B, a 18.82% decline from 2022.
- Novartis AG annual net total equity issued/repurchased for 2022 was $-10.552B, a 251.26% increase from 2021.
Novartis AG Annual Net Total Equity Issued/Repurchased
(Millions of US $) |
| 2024 |
$-8,301 |
| 2023 |
$-8,566 |
| 2022 |
$-10,552 |
| 2021 |
$-3,004 |
| 2020 |
$-2,842 |
| 2019 |
$-5,332 |
| 2018 |
$-2,036 |
| 2017 |
$-5,238 |
| 2016 |
$-895 |
| 2015 |
$-4,490 |
| 2014 |
$-6,915 |
| 2013 |
$-1,233 |
| 2012 |
$-97 |
| 2011 |
$-6,652 |
| 2010 |
$387 |
| 2009 |
$263 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$233.866B |
$50.317B |
|
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
|
